MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):626-9.
On October 16, 2009, the Food and Drug Administration (FDA) licensed bivalent human papillomavirus vaccine (HPV2; Cervarix, GlaxoSmithKline) for use in females aged 10 through 25 years. Cervarix is the second human papillomavirus (HPV) vaccine licensed for use in females in the United States. Quadrivalent HPV vaccine (HPV4; Gardasil, Merck & Co, Inc.) was licensed in 2006 for use in females aged 9 through 26 years, and the Advisory Committee on Immunization Practices (ACIP) recommended routine HPV4 vaccination of females aged 11 or 12 years, and catch-up vaccination for females aged 13 through 26 years. This report provides updated recommendations for routine and catch-up vaccination of females with either HPV2 or HPV4.
2009 年 10 月 16 日，美国食品和药物管理局（FDA）批准二价人乳头瘤病毒疫苗（HPV2；Cervarix，葛兰素史克）用于 10 至 25 岁女性。Cervarix 是美国批准用于女性的第二种人乳头瘤病毒（HPV）疫苗。四价 HPV 疫苗（HPV4；Gardasil，默克公司）于 2006 年获准用于 9 至 26 岁女性，免疫实践咨询委员会（ACIP）建议对 11 或 12 岁女性常规接种 HPV4 疫苗，并对 13 至 26 岁女性进行补种。本报告提供了更新的建议，用于常规和补种接种 HPV2 或 HPV4 的女性。
